Search Results

Entos Pharmaceuticals (Entos or the Company), a clinical-stage biotechnology company developing genetic medicines with its proprietary Fusogenix PLV nucleic acid delivery platform, and its partner, Aegis Life, Inc. (Aegis), today announced that Entos has received approval from Health Canada to initiate a phase 1/2 clinical trial (NCT06436911) evaluating Covigenix VAX-002, an investigational COVID-19 booster vaccine.

Entos Pharmaceuticals, (Entos), a genetic medicines company pioneering the development of life-changing medicines to patients with its Fusogenix PLV nucleic acid delivery technology, will be participating in the 2024 Bloom Burton & Co. Healthcare

Entos Pharmaceuticals announced the launch of its new Good Manufacturing Practices manufacturing facility in Carlsbad, California.

Entos Pharmaceuticals, Inc. (Entos), a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, and BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that they have entered into an agreement that will see Entos apply its Fusogenix nucleic acid delivery technology to promising gene therapy candidates in the BioMarin pipeline.

The Alberta Cancer Foundation is thrilled to announce that Entos Pharmaceuticals and 48Hour Discovery are the first recipients of its new Breakthrough Fund, an innovative, philanthropic vehicle that will support important research opportunities with the potential to accelerate cancer care and treatment through to commercialization.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Entos Pharmaceuticals, a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle nucleic acid delivery platform, announced the opening of its new 9,600 square foot research and development facility in the Torrey Pines community of San Diego, California.

Entos Pharmaceuticals, a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle nucleic acid delivery platform, announced the opening of its new 9,600 square foot research and development facility in the Torrey Pines community of San Diego, California.

Entos, Inc. today announced that it has appointed Jack Taunton, Professor of Cellular Molecular Pharmacology at University of California, San Francisco, and Ken Brameld, Senior Advisor for Samsara Biocapital, to the Company’s Scientific Advisory Board.